Essity B 263.4 (+1.1 SEK) on 15-Jul-2025 17:29
Select region

Global Site

Austria Austria Belgium Belgium Canada Canada Denmark Denmark Finland Finland France France Germany Germany Italy Italy Mexico Mexico Netherlands Netherlands Norway Norway Poland Poland Spain Spain Sweden Sweden United Kingdom United Kingdom USA USA

Did you mean

  • Spell suggestion...
Advanced search

Quick results

View all results

These might help

Corporate press releases

Corporate News

Investor Relations Calendar

Essity logo
Brands
Sustainability

Company

Company

Essity at a glance
Business Areas
Health & Medical Consumer Goods Professional Hygiene
Purpose and Strategy

Brands

Brands

Sustainability

Sustainability

Innovation

Innovation

Digitalization
Essity Ventures
Latest Innovations

Careers

Explore

Job Opportunities
Work at Essity
Commitment to Our Employees Learning and Development Why Choose Essity? Barrier Breakers
Students and Graduates
Graduates Students Internships Apprenticeships
Career Stories
Alumni Network
Connect with Us
Total Rewards

Media

Explore

Global News features
Global Press releases
US News
Images & Video
Essity in social media
Home
Media
Global Press releases
2021
Media
Global News features Global Press releases US News Images & Video Essity in social media

April 06, 2021

Essity acquires distribution rights to Sorbact in Australia and New Zealand

The leading global hygiene and health company Essity is acquiring the distribution rights to the wound care technology Sorbact® in Australia and New Zealand from the Australian company Bayport Brands. In 2020, sales of Sorbact® in the region amounted to AUD 1.7m (approximately SEK 11m). 

“This acquisition underlines our ambition to accelerate growth in advanced wound care, where we showed good organic sales growth during the second half of 2020. It is also a good fit for our strategy to establish a stronger presence in Australia and New Zealand, where we – in addition to our successful Medical Solutions operations – are also in the final phase of the acquisition of Asaleo Care,” says Magnus Groth, President and CEO of Essity.

Sorbact® is a clinically established innovation for advanced wound care, which is manufactured and marketed by Abigo Medical. Essity acquired 75% of Abigo Medical in February 2020. 

Sorbact® is used in wound care products to prevent and treat infections. It does this using a natural mode of action that binds bacteria and fungi. Sorbact® does not contain antiseptics or other toxic substances, which is positive for both the patient and the environment. 

Essity acquires distribution rights to Sorbact in Australia and New Zealand
Back to press releases

Share this

Essity logo
Brands Company Essentials Initiative Contact us California: Compliance Declaration 2025 Do not sell or share my personal data
Privacy Policy Supplemental State Privacy Policy Cookie Policy Terms and conditions Manage your choices

Tel 1 610 499 3700

© 2024 Essity | 2929 Arch Street, Suite 2600, Philadelphia, Pennsylvania 19104